EEG
AIMT

E.E. Geduld’s Aimmune Therapeutics AIMT Stock Holding History

E.E. Geduld’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-10,200
Closed -$258K – 230
2015
Q3 		$258K Buy
+10,200
New +$238K 0.24% 88

Other funds holding AIMT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
TG
TLP Group Evanston, Illinois $6.61M AUM 12.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

E.E. Geduld's AIMT Position: Q4 2015 in Review

E.E. Geduld sold out of Aimmune Therapeutics (AIMT) in Q4 2015, closing a stake of 10,200 shares — an estimated $258K sold.

E.E. Geduld first reported a position in AIMT in Q3 2015 and held it in 1 quarter. The position peaked at $258K in Q3 2015. 58 funds tracked by Wall St. Rank hold AIMT as of Q4 2015.

  • E.E. Geduld reported no remaining Aimmune Therapeutics position as of Q4 2015 after selling out during the quarter.
  • E.E. Geduld sold 10,200 Aimmune Therapeutics shares in Q4 2015, an estimated $258K.
  • E.E. Geduld first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 1 quarter.
  • E.E. Geduld's Aimmune Therapeutics position peaked at $258K in Q3 2015.
  • 58 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2015.

Based on E.E. Geduld's 13F filing for Q4 2015, filed 2 Feb 2016.